Sutro Biopharma, Inc. STRO
We take great care to ensure that the data presented and summarized in this overview for SUTRO BIOPHARMA, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding STRO
View all-
Suvretta Capital Management, LLC New York, NY7.46MShares$6.72 Million0.57% of portfolio
-
Black Rock Inc. New York, NY6.91MShares$6.22 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.21MShares$3.79 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ3.64MShares$3.28 Million0.42% of portfolio
-
Vestal Point Capital, LP New York, NY2.57MShares$2.31 Million0.28% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.46MShares$2.21 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.2MShares$1.98 Million0.01% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA2.2MShares$1.98 Million1.24% of portfolio
-
Bio Impact Capital LLC Cambridge, MA2.16MShares$1.94 Million0.59% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2MShares$1.8 Million0.01% of portfolio
Latest Institutional Activity in STRO
Top Purchases
Top Sells
About STRO
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Insider Transactions at STRO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 11
2025
|
Venkatesh Srinivasan CHIEF TECH OP OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
7,603
-12.74%
|
$0
$0.6 P/Share
|
|
Apr 11
2025
|
Venkatesh Srinivasan CHIEF TECH OP OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
21,250
+26.26%
|
-
|
|
Mar 05
2025
|
Edward C Albini CFO AND SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
3,594
-2.65%
|
$3,594
$1.36 P/Share
|
|
Mar 05
2025
|
Edward C Albini CFO AND SECRETARY |
BUY
Exercise of conversion of derivative security
|
Direct |
8,750
+6.06%
|
-
|
|
Mar 05
2025
|
Linda A Fitzpatrick CHIEF PEOPLE & COMM. OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,594
-3.63%
|
$3,594
$1.36 P/Share
|
|
Mar 05
2025
|
Linda A Fitzpatrick CHIEF PEOPLE & COMM. OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
8,750
+8.12%
|
-
|
|
Mar 05
2025
|
William J Newell CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,708
-2.24%
|
$6,708
$1.36 P/Share
|
|
Mar 05
2025
|
William J Newell CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,750
+5.9%
|
-
|
|
Mar 04
2025
|
Edward C Albini CFO AND SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
3,748
-2.87%
|
$3,748
$1.42 P/Share
|
|
Mar 04
2025
|
Edward C Albini CFO AND SECRETARY |
BUY
Exercise of conversion of derivative security
|
Direct |
9,125
+6.53%
|
-
|
|
Mar 04
2025
|
Linda A Fitzpatrick CHIEF PEOPLE & COMM. OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,748
-3.99%
|
$3,748
$1.42 P/Share
|
|
Mar 04
2025
|
Linda A Fitzpatrick CHIEF PEOPLE & COMM. OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
9,125
+8.85%
|
-
|
|
Mar 04
2025
|
Jane Chung Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,334
-2.32%
|
$2,334
$1.42 P/Share
|
|
Mar 04
2025
|
Jane Chung Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,875
+7.26%
|
-
|
|
Mar 04
2025
|
William J Newell CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,136
-3.82%
|
$11,136
$1.42 P/Share
|
|
Mar 04
2025
|
William J Newell CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
31,125
+9.64%
|
-
|
|
Mar 01
2025
|
Linda A Fitzpatrick CHIEF PEOPLE & COMM. OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
8,327
-8.93%
|
$8,327
$1.59 P/Share
|
|
Mar 01
2025
|
Linda A Fitzpatrick CHIEF PEOPLE & COMM. OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
20,275
+10.25%
|
-
|
|
Mar 01
2025
|
Jane Chung Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,450
-9.25%
|
$9,450
$1.59 P/Share
|
|
Mar 01
2025
|
Jane Chung Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
31,875
+13.91%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 410K shares |
|---|
| Payment of exercise price or tax liability | 154K shares |
|---|